Manager portfolios ·
Gavin Baker Portfolio Q2 2026: What Atreides Management Bought and Sold
Gavin Baker's Atreides Management Q2 2026 13F: top holdings, new buys, sales and returns vs the S&P 500, from the SEC filing of Aug 14.
Atreides Management, run by Gavin Baker, filed its Q2 2026 13F with the SEC on August 14, 2026, listing 46 positions worth $11.1B. Here is what changed from Q1 2026, the largest holdings, and how a portfolio copying them has done. The full holdings are on Gavin Baker's portfolio page.
Gavin Baker's top 10 holdings
| # | Stock | % of portfolio | Value | vs Q1 2026 |
|---|---|---|---|---|
| 1 | SPCX Space Ex Tech Spacex | 41.9% | $4.7B | New to top 50 |
| 2 | MU Micron Technology Inc | 7.4% | $821.1M | -6.5% shares |
| 3 | CBRS Cerebras Systems Inc | 6.2% | $687.3M | New to top 50 |
| 4 | ALAB Astera Labs Inc | 5.3% | $587.7M | -63.8% shares |
| 5 | CIEN Ciena Corp | 3.0% | $337.8M | +1.7% shares |
| 6 | CRDO Credo Technology Group Holdi | 2.8% | $307.1M | +3.5% shares |
| 7 | PANW Palo Alto Networks Inc | 2.7% | $299.1M | +56.1% shares |
| 8 | U Unity Software Inc | 2.6% | $292.8M | -17.3% shares |
| 9 | COHR Coherent Corp | 2.3% | $253.3M | +1.7% shares |
| 10 | NVDA Nvidia Corporation | 2.2% | $250.0M | +0.1% shares |
New to the top 50 in Q2 2026
- SPCX Space Ex Tech Spacex: 41.9% of the portfolio, $4.7B
- CBRS Cerebras Systems Inc: 6.2% of the portfolio, $687.3M
- META Meta Platforms Inc: 2.0% of the portfolio, $226.9M
- APH Amphenol Corp: 1.0% of the portfolio, $112.9M
- GTLB GitLab Inc: 0.9% of the portfolio, $103.0M
- CIFR Cipher Mining Inc: 0.8% of the portfolio, $87.9M
- IOT Samsara, Inc.: 0.7% of the portfolio, $74.9M
- PDFS Pdf Solutions Inc: 0.4% of the portfolio, $46.6M
- TTAN ServiceTitan, Inc.: 0.3% of the portfolio, $38.3M
- NTRA Natera Inc: 0.3% of the portfolio, $28.3M
Biggest additions
- PANW Palo Alto Networks Inc: +56.1% shares, now 2.7%
- CRWV Coreweave Inc: +162.2% shares, now 1.9%
- AKAM Akamai Technologies Inc: +33.4% shares, now 1.0%
- AFRM Affirm Hldgs Inc: +6.6% shares, now 0.9%
- WIX Wix.com Ltd: +124.2% shares, now 0.6%
- MA Mastercard Inc.: +88.8% shares, now 0.4%
What they sold
- LITE Lumentum Hldgs Inc: sold out (was 4.6%)
- ECHO Echostar Corp: sold out (was 2.9%)
- ZM Zoom Communications Inc: sold out (was 2.6%)
- RKT Rocket Cos Inc: sold out (was 2.1%)
- VST Vistra Corp: sold out (was 1.9%)
- RBLX Roblox Corporation: sold out (was 1.9%)
- HUBS Hubspot Inc: sold out (was 1.4%)
- SNPS Synopsys Inc: sold out (was 1.3%)
- MU Micron Technology Inc: -6.5% shares
- ALAB Astera Labs Inc: -63.8% shares
- U Unity Software Inc: -17.3% shares
- GOOGL Alphabet Inc: -12.0% shares
- TWLO Twilio Inc: -21.8% shares
- DKS Dicks Sporting Goods Inc: -17.1% shares
Has Gavin Baker beaten the market?
A portfolio holding Gavin Baker's 20 largest 13F positions, bought once each filing was public and rebuilt every quarter, returned +78.7% a year over 1 year (S&P 500 +20.1%), +49.4% a year over 3 years (S&P 500 +20.4%) and +18.5% a year over 5 years (S&P 500 +11.6%). 13Fs show only long US stock positions with up to a 45-day delay, so this measures the stock picks a cloner could have copied, not the fund's own returns.
Questions and answers
What stocks does Gavin Baker own?
As of the Q2 2026 13F, Gavin Baker's largest holdings are Space Ex Tech Spacex (SPCX) at 41.9%, Micron Technology Inc (MU) at 7.4%, Cerebras Systems Inc (CBRS) at 6.2%, Astera Labs Inc (ALAB) at 5.3% and Ciena Corp (CIEN) at 3.0%.
What did Gavin Baker buy in Q2 2026?
Positions new to its top 50 in Space Ex Tech Spacex (SPCX), Cerebras Systems Inc (CBRS), Meta Platforms Inc (META), Amphenol Corp (APH) and GitLab Inc (GTLB), and added to Palo Alto Networks Inc (PANW), Coreweave Inc (CRWV) and Akamai Technologies Inc (AKAM).
When is Gavin Baker's next 13F filing?
13F filings are due 45 days after each quarter ends; Atreides Management's next one is due by November 14, 2026.
Sources: SEC Form 13F-HR filed 2026-08-14. Written from the data on this site on Oct 29, 2026; every figure links to the page it comes from. Not investment advice.